PATENT CLAIM ANALYSIS

Application Number: 15873416
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "001100"]

Abstract:
The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Claim (Index 14):
The method of  claim 42  wherein reversal of the anticoagulant effect of the direct Factor Xa inhibitor results in the amount of thrombin being produced to increase by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, or 50-fold.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.11538
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12616735', '13414499', '13889014', '12239651', '13591098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8018168573614227
- 35 USC 102 Novelty (BERT): 0.5295150528545693
- Combined Prediction Score: 0.7745866769107373
- Mean Citation Score: 318.84791800000005
- Max Citation Score: 322.3307200000001
- Similarity Product: 166.70933089628224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test